ErbB-3 activation by NRG-1β sustains growth and promotes vemurafenib resistance in BRAF-V600E colon cancer stem cells (CSCs)

Approximately 5-10% of metastatic colorectal cancers harbor a BRAF-V600E mutation, which is correlated with resistance to EGFR-targeted therapies and worse clinical outcome. Vice versa, targeted inhibition of BRAF-V600E with the selective inhibitor PLX 4032 (Vemurafenib) is severely limited due to f...

Full beskrivning

Sparad:
Bibliografiska uppgifter
I publikationen:Oncotarget
Huvudupphovsmän: Prasetyanti, Pramudita R., Capone, Emily, Barcaroli, Daniela, D'Agostino, Daniela, Volpe, Silvia, Benfante, Antonina, van Hooff, Sander, Iacobelli, Valentina, Rossi, Cosmo, Iacobelli, Stefano, Medema, Jan Paul, De Laurenzi, Vincenzo, Sala, Gianluca
Materialtyp: Artigo
Språk:Inglês
Publicerad: Impact Journals LLC 2015
Ämnen:
Priority Research Paper
Länkar:https://ncbi.nlm.nih.gov/pmc/articles/PMC4627280/
https://ncbi.nlm.nih.gov/pubmed/26160848
Taggar: Lägg till en tagg
Inga taggar, Lägg till första taggen!

Liknande verk